TARS Tarsus Pharmaceuticals, Inc.
$79.31▼ -2.23%
Healthcare
Other
After hours
$79.31▲ +0.00%
Sep 11, 7:30 PM ET
Volume 490.8K
Avg Volume (10D) 980.7K
Key Metrics & Fundamentals
Market Cap
$3.48B
P/E Ratio
–
Div Yield
–%
52W Range
48.20 - 91.53
% vs 50 MA
17.31%
% vs 200 MA
15.21%
RSI-14
57.7
MACD Histogram
+0.2600
Beta (1Y vs SPY)
0.62
Free Cash Flow
$57.15M
Gross Rev
$173.91M
Gross Profit
$161.80M
EBITDA
-$15.66M
COGS
$12.11M
Operating Exp
$181.71M
Operating Income
-$19.91M
EBIT
-$19.91M
Pretax Income
-$15.84M
Net Income
-$18.55M
EPS (Diluted)
-0.43
Price & Volume History
Loading chart…
Recent News
Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing
MT Newswires · Sep 9, 2026 8:20 PM
Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing
MT Newswires · Sep 9, 2026 8:18 PM
Sector Update: Healthcare Stocks Decline Late Afternoon
MT Newswires · Sep 4, 2026 7:48 PM
Update: Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
MT Newswires · Sep 4, 2026 7:30 PM
Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals
MT Newswires · Sep 4, 2026 1:08 PM
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
GlobeNewswire · Sep 4, 2026 12:38 PM
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 1, 2026 8:30 PM
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
Simply Wall St. · Aug 13, 2026 11:14 PM
Tarsus (TARS) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 6:32 PM
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating
MT Newswires · Aug 12, 2026 12:34 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See TARS's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.